Maximizing Patient Outcomes for IO Sequencing in Advanced EC

Summary for Physicians:

Improving patient selection for IO sequencing is crucial to maximizing outcomes. One key approach is to refine biomarkers that can accurately predict which patients are most likely to benefit from IO therapy, such as microsatellite instability or tumor mutational burden. A better understanding of these biomarkers and their correlation with patient response could lead to more targeted treatment strategies. Additionally, incorporating a comprehensive genetic and molecular profile of each patient’s tumor can help identify those who are more likely to respond to specific immunotherapies. Other factors, such as the patient’s overall health, immune system status, and previous treatment history, should also be considered to ensure the optimal selection for IO sequencing. Implementing these strategies in clinical practice could improve patient outcomes by offering the right therapies to the right patients at the right time.